News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Pharmaceutical Technology on MSN6d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demandNovo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.
Within six months, the drug reduced the risk of cardiovascular death by 50 and cut the risk of needing urgent treatment due to heart failure.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback